Key facts
- This page summarizes Mardi Dier's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 06 Jan 2026, 16:44.
Mardi Dier - 02 Jan 2026 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)
- Reporting relationship
- Director
- Issuer ticker
- ORIC
- Reported as of
- 02 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2026, 16:44:42 UTC
- Prior SEC filing
- 03 Dec 2025
- Next SEC filing
- 02 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Kuhlen, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mardi Dier filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 06 Jan 2026.
Change
- Previous filing in this sequence was filed on 03 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001574591
Primary reporting owner
Dier Mardi
- Relationship
- Director
- Address
- C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
- Signature
- /s/ Christian Kuhlen, attorney-in-fact
- Signature date
- 06 Jan 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORIC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 02 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $8.17
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.